Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

被引：0
|
作者：
Nishikawa, K. [1 ]
Koizumi, W. [2 ]
Tsuburaya, A. [3 ]
Yamanaka, T. [4 ]
Morita, S. [5 ]
Fujitani, K. [6 ]
Akamaru, Y. [7 ]
Shimada, K. [8 ]
Hosaka, H. [9 ]
Nakayama, N. [10 ]
Miyashita, Y. [11 ]
Tsujinaka, T. [12 ]
Sakamoto, J. [13 ]
机构：
[1] Natl Hosp Org Osaka Natl Hosp, Surg, Osaka, Japan
[2] Kitasato Univ, Sch Med, Gastroenterol, Sagamihara, Kanagawa, Japan
[3] Tsuboi Canc Ctr Hosp, Surg, Koriyama, Fukushima, Japan
[4] Yokohama City Univ Med, Biostat, Yokohama, Kanagawa, Japan
[5] Kyoto Univ, Grad Sch Med, Biomed Stat & Bioinformat, Kyoto, Japan
[6] Osaka Gen Med Ctr, Surg, Osaka, Japan
[7] Ikeda Municippal Hosp, Surg, Ikeda, Osaka, Japan
[8] Showa Univ, Kouto Toyosu Hosp, Internal Med, Tokyo, Japan
[9] Gunma Prefectural Canc Ctr, Gastroenterol, Ohta, Gunma, Japan
[10] Kanagawa Canc Ctr, Gastroenterol, Yokohama, Kanagawa, Japan
[11] Epidemiol & Clin Res Informat Network, Ctr Data, Okazaki, Aichi, Japan
[12] Kaizuka City Hosp, Surg, Kaizuka, Japan
[13] Tokai Cent Hosp, Surg, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
679P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy
    Kazuhiro Nishikawa
    Wasaburo Koizumi
    Akira Tsuburaya
    Motoko Suzuki
    Satoshi Morita
    Kazumasa Fujitani
    Yusuke Akamaru
    Ken Shimada
    Hisashi Hosaka
    Ken Nishimura
    Takaki Yoshikawa
    Toshimasa Tsujinaka
    Junichi Sakamoto
    International Journal of Clinical Oncology, 2025, 30 (2) : 320 - 329
  • [2] Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer
    Nishikawa, Kazuhiro
    Koizumi, Wasaburo
    Tsuburaya, Akira
    Yamanaka, Takeharu
    Morita, Satoshi
    Fujitani, Kazumasa
    Akamaru, Yusuke
    Shimada, Ken
    Hosaka, Hisashi
    Nakayama, Norisuke
    Tsujinaka, Toshimasa
    Sakamoto, Junichi
    GASTRIC CANCER, 2020, 23 (01) : 160 - 167
  • [3] Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer
    Kazuhiro Nishikawa
    Wasaburo Koizumi
    Akira Tsuburaya
    Takeharu Yamanaka
    Satoshi Morita
    Kazumasa Fujitani
    Yusuke Akamaru
    Ken Shimada
    Hisashi Hosaka
    Norisuke Nakayama
    Toshimasa Tsujinaka
    Junichi Sakamoto
    Gastric Cancer, 2020, 23 : 160 - 167
  • [4] BIWEEKLY COMBINATION CHEMOTHERAPY OF DOCETAXEL, IRINOTECAN AND CISPLATIN AS SECOND-LINE TREATMENT FOR ADVANCED GASTRIC CANCER
    Denda, T.
    Sudo, K.
    Nakamura, K.
    Hara, T.
    Yamaguchi, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
  • [5] Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
    Higuchi, Katsuhiko
    Tanabe, Satoshi
    Shimada, Ken
    Hosaka, Hisashi
    Sasaki, Eisaku
    Nakayama, Norisuke
    Takeda, Yuiti
    Moriwaki, Toshikazu
    Amagai, Kenji
    Sekikawa, Takashi
    Sakuyama, Toshikazu
    Kanda, Tatsuo
    Sasaki, Tohru
    Azuma, Mizutomo
    Takahashi, Fumiaki
    Takeuchi, Masahiro
    Koizumi, Wasaburo
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (08) : 1437 - 1445
  • [6] Meta-analysis of irinotecan monotherapy versus irinotecan-based combined second-line therapy for the treatment of advanced gastric cancer
    Xu, Jia
    Zhang, Zi-Zhen
    Lin, Tian-Long
    Cao, Hui
    Yang, Han-Kwang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 13712 - +
  • [7] Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
    Cho, Yo-Han
    Yoon, So Young
    Kim, Soo-Nyung
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 255 - 262
  • [8] Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen
    Schüll, B
    Kornek, GV
    Schmid, K
    Raderer, M
    Ulrich-Pur, H
    Fiebiger, W
    Schneeweiss, B
    Lenauer, A
    Depisch, D
    Scheithauer, W
    ONKOLOGIE, 2002, 25 (04): : 358 - 362
  • [9] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
    Taroh Satoh
    Kyung Hee Lee
    Sun Young Rha
    Yasutsuna Sasaki
    Se Hoon Park
    Yoshito Komatsu
    Hirofumi Yasui
    Tae-You Kim
    Kensei Yamaguchi
    Nozomu Fuse
    Yasuhide Yamada
    Takashi Ura
    Si-Young Kim
    Masaki Munakata
    Soh Saitoh
    Kazuto Nishio
    Satoshi Morita
    Eriko Yamamoto
    Qingwei Zhang
    Jung-mi Kim
    Yeul Hong Kim
    Yuh Sakata
    Gastric Cancer, 2015, 18 : 824 - 832
  • [10] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
    Satoh, Taroh
    Lee, Kyung Hee
    Rha, Sun Young
    Sasaki, Yasutsuna
    Park, Se Hoon
    Komatsu, Yoshito
    Yasui, Hirofumi
    Kim, Tae-You
    Yamaguchi, Kensei
    Fuse, Nozomu
    Yamada, Yasuhide
    Ura, Takashi
    Kim, Si-Young
    Munakata, Masaki
    Saitoh, Soh
    Nishio, Kazuto
    Morita, Satoshi
    Yamamoto, Eriko
    Zhang, Qingwei
    Kim, Jung-mi
    Kim, Yeul Hong
    Sakata, Yuh
    GASTRIC CANCER, 2015, 18 (04) : 824 - 832
12345